解决糖尿病海需要扩大对糖尿病技术的访问
Davida F Kruger1, Christopher G Parkin2, Irl B Hirsch3
1Division of Endocrinology, Diabetes, Bone & Mineral, Henry Ford Health System, Detroit, MI, USA.
Journal of diabetes science and technology
|April 10, 2025
概括
持续血糖监测 (CGM) 和自动胰岛素输送 (AID) 改善了糖尿病护理,但由于限制性保险标准,它们往往无法获得. 本次审查审查了证据,并建议扩大对这些改善生活的技术的访问.
科学领域:
- 内分泌学 在内分泌学.
- 医疗技术 医疗技术 医学技术
- 卫生经济学 卫生经济学
背景情况:
- 持续血糖监测 (CGM) 和自动胰岛素输送 (AID) 为糖尿病管理提供了显著的好处.
- 这些先进技术可以提高患者的治疗结果,改善生活质量,并可能降低长期医疗保健成本.
- 然而,由于保险提供商的资格标准,访问往往受到限制.
研究的目的:
- 审查支持CGM和AID在不同糖尿病人群中使用的证据.
- 分析当前的保险资格标准,限制这些技术的使用.
- 建议修订标准,以改善患者获得医疗服务.
主要方法:
- 这项研究采用了叙事审查和评论方法.
- 在各种糖尿病人群中合成了支持CGM和AID疗效的证据.
- 检查了当前保险资格标准的限制性.
主要成果:
- CGM和AID对糖尿病患者有明显的好处.
- 现有的保险标准排除了许多可以从这些技术中获益的患者.
- 这些设备的潜在实用性和可访问性之间存在很大的差距.
结论:
- 扩大获得CGM和AID的机会对于改善糖尿病护理至关重要.
- 修改目前的保险资格标准是必要的,以确保更广泛的患者福利.
- 建议改变政策,以促进这些技术的更广泛采用.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Management and Pharmacotherapy
214
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
487
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
487
Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Glucagon-like Receptor Agonists
272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272


